Physician profile
Bryson Oneil
NPI 1114376852
$28,863.99
in general payments reported to CMS, 2019-2025
29 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,200 · 2024: $4,999 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $13K · Education: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,150.00 |
| Food and Beverage | $12,982.21 |
| Education | $731.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $16,934.13 | 2023-2025 | Nemluvio, Aklief, Twyneo |
| Abbvie INC. | $2,469.28 | 2023-2025 | |
| Janssen Biotech, INC. | $1,986.35 | 2023-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $912.69 | 2023-2025 | |
| Ucb, INC. | $773.16 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $757.56 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $646.47 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $634.90 | 2023-2025 | Dupixent, Libtayo |
| Incyte Corporation | $475.89 | 2023-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $414.17 | 2023-2024 | Sotyktu |
| Pfizer INC. | $382.87 | 2023-2025 | |
| Lilly USA, LLC | $380.67 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $371.98 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $317.95 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $308.11 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $245.98 | 2023-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $179.98 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $112.04 | 2023-2025 | Cabtreo, Siliq |
| Almirall LLC | $106.85 | 2024-2025 | Seysara, Klisyri |
| Medimetriks Pharmaceuticals, INC. | $90.45 | 2025 | Neo-Synalar, Clindacin Etz |
| Botanix Sb INC | $58.49 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $55.40 | 2023-2024 | Idacio |
| Organon LLC | $50.67 | 2025 | Vtama |
| Journey Medical Corporation | $49.78 | 2024-2025 | |
| Kyowa Kirin, INC. | $43.40 | 2024 | Poteligeo |
| Leo Pharma INC. | $31.73 | 2024-2025 | Adbry |
| Biofrontera INC. | $29.61 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Fidia Pharma USA INC. | $24.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.58 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryson Oneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.